Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 4/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461480 | 1.00 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL1462556 | 0.98 | DNM1 (0.44) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL1462680 | 0.91 | — | — | |
| SCHEMBL1462568 | 0.80 | — | — | |
| SCHEMBL7346446 | 0.80 | S1PR2 (0.50) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL9550792 | 0.79 | DNM1 (0.44) | DNM1KDM5AKDM4CPHF8TSHR | |
| SCHEMBL7611885 | 0.79 | DNM1 (0.44) | DNM1KDM5AKDM4CPHF8TSHR | |
| SCHEMBL1461490 | 0.79 | DNM1 (0.44) | DNM1KDM5AKDM4CPHF8TSHR | |
| SCHEMBL5985439 | 0.77 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL24103978 | 0.77 | DNM1 (0.67) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694858-B1 | METHOD FOR DETECTING PATHOGENIC MYCOBACTERIA IN CLINICAL SPECIMENS | COUNCIL SCIENT IND RES (IN) | 2009-06-17 | — | — | EP | claimed |
| US-20230272439-A1 | METHOD FOR PRODUCING OLIVETOLIC ACID IN AN AMOEBOZOA HOST SPECIES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E. V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4176054-A1 | METHOD FOR PRODUCING OLIVETOLIC ACID IN AN AMOEBOZOA HOST SPECIES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022003126-A1 | METHOD FOR PRODUCING OLIVETOLIC ACID IN AN AMOEBOZOA HOST SPECIES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E. V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| EP-3215496-B1 | PANTOTHENAMIDE ANALOGUES | RADBOUD UNIV MEDISCH CENTRUM (NL) | 2019-01-02 | — | — | EP | disclosed |
| EP-3287126-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3215496-A2 | PANTOTHENAMIDE ANALOGUES | Radboud Universitair Medisch Centrum (NL) | 2017-09-13 | — | — | EP | disclosed |
| US-20170182015-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | SUNESIS PHARMACEUTICALS INC (US) | 2017-06-29 | — | — | US | disclosed |
| US-6211336-B1 | AMINO ACID SEQUENCE USED IN THE DIAGNOSIS AND TREATMENT OF NERVOUS SYSTEM GENETIC DISORDER; FOR CANCER SCREENING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-04-03 | — | — | US | disclosed |
| US-6200749-B1 | AJUSTED NUCLEIC ACID SEQUENCE; FOR DETECTION OF GENOME ADJUSTMENTS AND PREFERENTIAL GENETIC DISORDERS | RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2001-03-13 | — | — | US | disclosed |
| EP-1073748-A2 | VACCINES CONTAINING RECOMBINANT PILIN AGAINST NEISSERIA GONORRHOEAE OR NEISSERIA MENINGITIDIS | AMERICAN CYANAMID COMPANY (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0826033-A4 | ATAXIA-TELANGIECTASIA GENE | UNIV RAMOT (IL) | 2000-09-06 | — | — | EP | disclosed |
| EP-0826031-A4 | ATAXIA-TELANGIECTASIA GENE AND ITS GENOMIC ORGANIZATION | UNIV RAMOT (IL) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999055875-A2 | VACCINES CONTAINING RECOMBINANT PILIN AGAINST NEISSERIA GONORRHOEAE OR $i(NEISSERIA MENINGITIDIS) | AMERICAN CYANAMID COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0826033-A1 | ATAXIA-TELANGIECTASIA GENE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826031-A1 | ATAXIA-TELANGIECTASIA GENE AND ITS GENOMIC ORGANIZATION | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036695-A1 | ATAXIA-TELANGIECTASIA GENE | RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT, LTD. (IL) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996036691-A1 | ATAXIA-TELANGIECTASIA GENE AND ITS GENOMIC ORGANIZATION | RAMOT-UNIV. AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182015-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | BRCA1, MRE11, RAD51 | DNM1 2503/4885S1PR2 1118/4885S1PR1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.